ATLANTA, GA – – (Globe Newswire – July 27, 2023) – – Holzer & Holzer, LLC is investigating whether Kodiak Sciences Inc. (“Kodiak” or the “Company”) (NASDAQ: KOD) complied with federal securities laws.  On July 24, 2023, Kodiak released top line results from several Phase 3 studies, noting the “GLEAM and GLIMMER studies did not meet their primary efficacy endpoints” and announcing that the Company decided to discontinue further development of its product, tarcocimab. Following this news, the price of the Company’s stock dropped.

If you purchased Kodiak stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/kodiak/ to discuss your legal rights.

Registration Deadline

Lead Plaintiff Deadline Has Passed

Submit Your Information

Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share